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Smad7 is a negative feedback product of TGF-β superfamily signaling
and fine tunes a plethora of pleiotropic responses induced by
TGF-β ligands. However, its noncanonical functions independent
of TGF-β signaling remain to be elucidated. Here, we show that
Smad7 activates signal transducers and activators of transcription 3
(STAT3) signaling in maintaining mouse embryonic stem cell pluripo-
tency in a manner independent of the TGF-β receptors, yet depen-
dent on the leukemia inhibitory factor (LIF) coreceptor glycoprotein
130 (gp130). Smad7 directly binds to the intracellular domain of
gp130 and disrupts the SHP2–gp130 or SOCS3–gp130 complex,
thereby amplifying STAT3 activation. Consequently, Smad7 facili-
tates LIF-mediated self-renewal of mouse ESCs and is also critical
for induced pluripotent stem cell reprogramming. This finding il-
lustrates an uncovered role of the Smad7–STAT3 interplay in main-
taining cell pluripotency and also implicates a mechanism involving
Smad7 underlying cytokine-dependent regulation of cancer
and inflammation.
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Members of the TGF-β superfamily, including TGF-β,Activin, Nodal, and BMP, play a major role in maintaining
pluripotency in stem cells and controlling cell fate determination
during development (1–4). In cell culture, BMP4 and leukemia
inhibitory factor (LIF) are required to maintain pluripotency (5).
BMP induces Id proteins to suppress differentiation and sustain
embryonic stem cell (ESC) self-renewal (6). Although being in-
dispensable for ESC propagation, TGF-β/Activin/Nodal induce
differentiation of ESCs in the absence of LIF (7). During mouse
fibroblast reprogramming into ES-like cells by Oct4, KLF4,
c-Myc, and Sox2 or alternatives (8), BMP enhances reprogram-
ming into induced pluripotent stem cells (iPSCs) (9, 10), while
TGF-β signaling exerts an inhibitory effect on iPSC induction
(11, 12). Thus, in response to morphogen gradients of the TGF-β
superfamily ligands, the cellular outcome is determined by in-
tegration of their balanced signaling activities.
Signals of the TGF-β superfamily are transduced by intracellular
R-Smads, i.e., BMP-activated Smad1, Smad5, and Smad8, and
TGF-β/Activin/Nodal-activated Smad2 and Smad3. Smad7, in-
duced by all ligands of the TGF-β superfamily, can act as a negative
feedback product to inhibit TGF-β signaling (13, 14). Smad7 can
compete with R-Smads for binding to the type I receptor (e.g.,
TβRI) (15–17), recruit the HECT E3 ubiquitin ligases to promote
proteasomal degradation of the receptor proteins (18), or recruit
protein phosphatase 1 to inactivate the type I receptor (19, 20).
In addition, Smad7 also disrupts the association of functional
R-Smad–Smad4 complexes as well as binding of R-Smads complex
to DNA in the nucleus (21). Certain cytokines such as IFN-γ in-
duce expression of Smad7 to suppress TGF-β/BMP signaling (22).
Although it modulates NF-κB, c-Jun N-terminal kinase (JNK)/p38,
and Wnt signaling (23–25), Smad7 has been thought to function
primarily through its inhibitin on both TGF-β and BMP signaling.
It has been reported that Smad7 directly converts human ESCs to
telencephalic fate (26) and promotes self-renewal of mouse he-
matopoietic stem cells (27). In mouse ESCs, an increased level of
Smad7 due to loss of its E3 ligase RNF12 impairs both activin-
induced anterior mesoderm formation and BMP-mediated re-
pression of neural induction (28). Despite all these studies on
Smad7, it remains elusive whether Smad7 acts through a non–
TGF-β pathway to impact ESC pluripotency.
LIF and related cytokines signal through the glycoprotein 130
(gp130) and signal transducers and activators of transcription 3
(STAT3) (29–34). Following the engagement of LIF to its re-
ceptor complex containing gp130, Janus kinases (JAKs) become
catalytically activated. Activated JAKs phosphorylate tyrosine
residues in the intracellular domain of gp130, which serves as
docking sites for the Src homology 2 (SH2) domains of STATs
(35, 36). When bound to gp130 and JAK, STATs are phos-
phorylated, translocate to the nucleus, and then bind to the
STAT-binding elements in the target genes. Termination of the
gp130–STAT3 signaling is effectuated by several mechanisms,
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including dephosphorylation of gp130 by the SH2-containing
phosphatase (SHP2) (37) and negative feedback inhibition by
the suppressor of cytokine signaling (SOCS) proteins (38).
In regulating ESC pluripotency, LIF-activated STAT3 functions
through its cooperation with the core pluripotency transcription
factors such as Oct4, Nanog, and Sox2 (39). Smad1/5/8 also co-
operate with Oct4, Nanog, and Sox2 as well as STAT3 to maintain
pluripotency (39). In addition, STAT3 can promote expression of
TGF-β1 (40) and Smad7 (41, 42). STAT3 also selectively interacts
with Smad3 to antagonize TGF-β signaling (43), whereas Smads
attenuate the STAT3 signaling through an inhibition of STAT3
binding to DNA and cooperation with p300 (44). However, it re-
mains unknown whether Smad7, induced by both TGF-β and
STAT3 signaling, directly cross-talks with STAT3 signaling to in-
fluence ESC pluripotency. In this study, we identified and char-
acterized a direct interaction between Smad7 and gp130 that leads
to Smad7-mediated amplification of the gp130–STAT3 signaling
and maintenance of embryonic pluripotency. This unexpected ac-
tion of Smad7 is independent of its inhibitory effect on TGF-
β/BMP signaling. Our findings elucidate a mechanism underlying
the modulation of the gp130–STAT3 axis by Smad7 and identify
the essential role of Smad7 as a critical cell fate regulator.
Results
Smad7 Attenuates Mouse ESC Differentiation. Smad7 has been
identified as a STAT3 target gene, and it is abundantly expressed
in mouse ESCs (41, 42). We first investigated whether the ex-
pression of Smad7 changes during embryoid body (EB) differ-
entiation derived from mouse ESCs. During cell differentiation,
we observed an apparently gradual decrease in expression of
Smad7, which was accompanied by the decrease of pluripotency
markers including Oct4, Nanog, and Sox2 (Fig. 1A and Fig. S1A),
whereas expression of differentiation markers such as Brachyury/T,
Foxa2, and Cxcl12 profoundly increased (Fig. S1B). These results
indicate a high expression level of Smad7 may be required for the
undifferentiated state of ESCs.
To further investigate whether Smad7 regulates ES cell fate
determination, stable and inducible expression of Smad7 was estab-
lished in the mouse ES cell line CGR8 using the tetracycline-
inducible (tet-on) system, designated as SFB–Smad7–tet-on
cells. Doxycycline (Dox) treatment induced a moderate expres-
sion of Smad7 in SFB–Smad7–tet-on cells (Fig. S1 C and D).
During EB differentiation, Oct4, Nanog, and Sox2 as well as
endogenous Smad7 were reduced at day 4 of differentiation, yet
Dox-induced expression of Smad7 maintained high expression
levels of these pluripotency markers (Fig. 1B and Fig. S1E). In
contrast, induced expression of Smad7 markedly decreased ex-
pression of differentiation markers of all three germ layers, in-
cluding ectodermal markers (i.e., Cxcl12 and SOX17), mesodermal
markers (i.e., Brachyury/T and BMP5), and endodermal markers
(i.e., Foxa2 and Gata4) at day 4 of EB differentiation (Fig. 1C).
These results imply that Smad7 promotes self-renewal of
mouse ESCs.
Smad7 Is Essential in Promoting ESC Self-Renewal and iPSC
Reprogramming. We next determined whether loss of Smad7 ex-
pression could enhance ESC differentiation. In mESCs, stably
expressed shSmad7 (Fig. S2A) reduced the mRNA and protein
levels of Oct4, Nanog, and Sox2 (Fig. 2A and Fig. S2B). By using
immunofluorescence, a profound loss of Oct4 expression was
observed in shSmad7-expressing cells (Fig. 2B). Consistently,
shSmad7 resulted in low alkaline phosphatase (AP) activ-
ity (Fig. 2C). Notably, an shRNA-resistant variant of Smad7
(FLAG-tagged Smad7r, Fig. S2 C and D) completely rescued
the effect of shSmad7 on ESC differentiation (Fig. 2 A–C and
Fig. S2B), demonstrating the specific on-target effect of
shSmad7. In addition, shSmad7 induced the mRNA and pro-
tein levels of ectodermal markers (i.e., Cxcl12 and Fgf5) and
mesodermal markers (i.e., Brachyury/T and BMP5), but not
endodermal or trophectodermal markers (Fig. 2D and Fig. S2E).
Furthermore, transient knockdown of Smad7 exhibited the same
effect on ESC self-renewal and differentiation (Fig. S2F). Thus,
our results strongly support a direct role of Smad7 in maintaining
ESC self-renewal.
Given the positive role of Smad7 in promoting ESC self-
renewal, we were interested in determining whether Smad7 has a
critical role in iPSC reprogramming. We used four conventional
reprogramming factors, i.e., Oct4, Sox2, KLF4, and c-Myc (OSKM),
to induce pluripotency in mouse embryonic fibroblasts (MEFs).
Fig. 1. Smad7 promotes self-renewal and inhibits differentiation of ESCs. (A) Smad7 is down-regulated during EB formation in CGR8 cells. qRT-PCR was used
to analyze mRNA levels of Smad7, Oct4, Sox2, Nanog, and GAPDH. Data are shown as mean ± SEM; n = 3. (B) Smad7 maintains a high expression level of
pluripotency markers during EB formation. SFB–Smad7–tet-on CGR8 underwent EB differentiation for 4 d in the absence or presence of 1 μg/mL Dox. Total
RNAs were subjected to qRT-PCR to examine expression levels of Oct4, Nanog, Sox2, and Smad7. Data are shown as mean ± SEM; n = 3. *P < 0.05.
(C) Smad7 inhibits ESC differentiation during EB formation. The experiment was essentially performed as described in Fig. 1B, and qRT-PCR was used to
examine mRNA levels of ectoderm, mesoderm, and endoderm markers. Data are shown as mean ± SEM; n = 3. *P < 0.05.
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Accompanied by the increased expression of OSKM, we observed
an increase in the expression of Smad7 (Fig. S2G). We then
further determined the role of Smad7 in iPSC reprogramming.
While OSKM could produce as high as 25% reprogramming
efficiency in Oct4–GFP MEFs, as indicated by AP- and GFP-
positive iPSC colonies, shSmad7 markedly reduced the number
of OSKM-induced iPSC colonies (Fig. 2 E and F). Our results
indicate that depletion of Smad7 profoundly blocks OSKM-
mediated reprogramming into iPSCs.
Smad7 Regulates Pluripotency Independent of TGF-β/BMP Signaling.
We next attempted to determine whether Smad7 regulates plu-
ripotency through canonical inhibition of TGF-β/BMP signaling.
We first examined the effects of small molecule inhibitors
SB431542 against TGF-β type I receptor or Dorsomorphin
against BMP type I receptor, named TGFBRi and BMPRi, re-
spectively. Dox-induced expression of Smad7 could suffice to
moderately increase expression of pluripotency markers, espe-
cially Oct4 and Nanog, which was further increased by addition
of exogenous LIF (Fig. 3A). It is not surprising that TGFBRi or
BMPRi had no effects on Smad7-induced up-regulation of
Nanog, Oct4, and Sox2 (Fig. 3A) as Smad7 itself is a potent in-
hibitor of TGF-β/BMP signaling. Remarkably, the effect of
Smad7 depletion on expression of pluripotency markers, as ei-
ther measured by Western blotting analysis (Fig. 3B) or immu-
nofluorescence (Fig. S3A) or AP activity (Fig. S3B), remained
unchanged after treatment with TGFBRi or BMPRi. Further-
more, the Smad7 mutant K401E, which was defective in binding
to the type I receptor (45), failed to effectively inhibit TGF-β or
BMP signaling (Fig. S3 C and D) and notably retained its ability
to promote expression of ESC pluripotency markers (Fig. S3E).
These findings clearly demonstrated that the function of
Smad7 in controlling ESC pluripotency may not rely on its
negative regulation of TGF-β–Smad signaling.
Smad7 Activates STAT3 Independent of TGF-β Receptor Signaling.
Smad7 is not only induced by TGF-β signaling, but also by
JAK–STAT signaling (41, 42, 46). We sought to determine
whether increased expression of Smad7 could affect STAT3
activation. In CGR8 SFB–Smad7–tet-on cells, Dox induced ex-
pression of SFB-tagged Smad7 (Fig. 4A, lanes 6 and 8) and
promoted LIF-induced STAT3 phosphorylation at Y705 (p-STAT3),
indicative of STAT3 activation (Fig. 4A, lane 8). Smad7 ap-
parently enabled ESCs to be more sensitive to LIF (short time
or low dosage) in STAT3 activation and Oct4 expression
(Fig. S4 A and B). As a consequence, Dox induced a higher
level of endogenous SOCS3 mRNA (a STAT3 target gene)
(Fig. 4B) and also a significantly higher level of LIF-induced
M67-luc reporter activity (Fig. S4C). In sharp contrast,
Dox did not alter the levels of p-STAT3, SOCS3 mRNA,
and M67-luc activity in control (Ctrl) cells (Fig. 4 A and B
and Fig. S4C).
We then determined whether Smad7-enabled STAT3 activa-
tion requires TGF-β receptor signaling. We found that the
Smad7 mutant K401E, defective in binding to the type I re-
ceptor, was as potent as wild-type Smad7 in activating STAT3
(Fig. 4C). TGFBRi or BMPRi had no effects on Smad7-induced
STAT3 activation (Fig. S4D). Notably, TGFBRi or BMPRi
could not reverse the effect of shSmad7 on LIF-mediated
STAT3 activation (Fig. 4D). Thus, our results suggest that
Smad7 potentiates STAT3 signaling independent of its inhibitory
effects on TGF-β signaling.
Smad7 Directly Binds to gp130 and Disrupts the SHP2/SOCS3 Binding
to gp130. Because Smad7 promotes LIF-induced STAT3 activa-
tion, we speculated that Smad7 might interact with the LIF–
gp130–STAT3 pathway. Indeed, we found that Smad7 bound to
gp130, a coreceptor for LIF in transfected cells in coimmuno-
precipitation (co-IP) assays (Fig. S5A). Further, Smad7 could
interact with gp130 at the endogenous levels (Fig. 5A). We also
conducted an in vitro binding assay using purified recombinant
proteins. As shown in Fig. 5B, His-tagged gp130–ICD protein
(the cytoplasmic domain of gp130) could bind to Smad7, but not
GFP protein, indicating that Smad7 directly binds to the cyto-
plasmic domain of gp130.
To determine the structural features for the Smad7–gp130
interaction, we first mapped the domain of Smad7 for gp130
binding. Our co-IP assay revealed that both wild-type and the
MH2 or C domain (aa 228–426) of Smad7, but not the N domain
Fig. 2. Smad7 is essential in maintenance of pluripotency. (A–C) Depletion
of Smad7 down-regulates expression of pluripotency markers and induces
differentiation in ESCs. CGR8 cells stably expressing shSmad7 were estab-
lished as described in Supporting Information. Smad7r is a RNAi-resistant
variant of Smad7. (A) qRT-PCR analysis of Oct4, Nanog, Sox2, and Smad7.
Data are shown as mean ± SEM; n = 3. (B) Immunofluorescence analysis of
Oct4. DNA was stained with DAPI. (C) AP staining of CGR8 cells stably
expressing shSmad7 and/or Smad7r. (D) Depletion of Smad7 enhances ESC
differentiation into ectoderm and mesoderm, but not endoderm or tro-
phectoderm. qRT-PCR was used to examine mRNA levels of indicated dif-
ferentiation markers. Data are shown as mean ± SEM; n = 3. *P < 0.05, **P <
0.01. (E and F) Smad7 depletion inhibits the reprogramming efficiency in
reprogrammable MEFs. Reprogrammed iPSC colonies were identified by AP
staining (E) and quantitation of GFP-positive clones (F) at day 14. Data are
shown as mean ± SEM; n = 3. **P < 0.01.
Fig. 3. Smad7 promotes pluripotency independent of canonical TGF-β/Smad
signaling. (A) Smad7 promotes ESC self-renewal independent of TGF-β/BMP
signaling. SFB–Smad7–tet-on cells were pretreated with 5 μM SB431542
(TGFBRi) or 10 μM Dorsomorphin (BMPRi) for 12 h and then cultured in in-
dicated medium for another 3 d. qRT-PCR was used to analyze expression of
indicated pluripotency markers. Data are shown as mean ± SEM; n = 3.
(B) Inhibition of TGF-β/BMP signaling does not reverse the effect of
siSmad7 in ESC pluripotency. CGR8 cells were transfected with 40 pM
Smad7 siRNA or control siRNA and cultured with TGFBRi or BMPRi for 2 d.
Cell lysates were subjected to Western blot analysis.








(amino acids 1–228), bound to gp130 (Fig. S5B). On the
gp130 side, a series of HA-tagged deletions in gp130–ICD were
tested for their interactions with FLAG–Smad7 in HEK293T
cells (Fig. S5C). The mutant containing amino acids 616–918,
616–889, or 616–764 retained the ability to interact with Smad7,
whereas the amino acids 616–734 and 616–646 mutants did not
bind to Smad7 (Fig. S5C), indicating that residues 734–764 could
be potentially critical for the Smad7 binding.
The 734–764 aa region of gp130 has a critical phosphotyrosine-
759 (pY759). SHP2 and SOCS3 are recruited to the pY759 residue
to block STAT3 activation (37, 38). We then asked whether
Smad7 blocks the binding of SHP2/SOCS3 to gp130. GST–gp130–
Y759E (mimicking Y759 phosphorylation) and His–SHP2 were
coexpressed in Escherichia coli and the preformed complex be-
tween gp130–Y759E and SHP2 was retrieved using glutathione
beads (Fig. S5D). Interestingly, when added to the purified gp130–
Y759E/SHP2 complex in vitro, increasing amounts of recombinant
His–Smad7 protein competitively replaced His–SHP2 for binding
to GST–gp130–Y759E with an approximate Ki of 0.30 μM (Fig.
5C). These results demonstrate that Smad7 directly competes with
SHP2 for gp130 binding.
We further assessed the effect of Smad7 on endogenous
gp130–SHP2 or gp130–SOCS3 interactions in CGR8 cells. Lentiviral
expression of exogenous Smad7 profoundly blocked binding of
endogenous SHP2 or SOCS3 to gp130 (Fig. 5D, lane 4). Fur-
thermore, shSmad7 markedly increased the physiological in-
teraction of either SHP2 or SOCS3 with gp130 in CGR8 cells
(Fig. 5D, lane 8). Collectively, our data suggest that Smad7 promotes
gp130-mediated STAT3 signaling by overriding SHP2/SOCS3-
mediated inhibition.
Smad7 Promotes Pluripotency Through Blocking SHP2 and SOCS3.
Having established the molecular antagonism between Smad7
and SHP2 or SOCS3 during STAT3 activation, we further assessed
the relationship among Smad7, STAT3, and SHP2/SOCS3 in
maintaining ESC pluripotency. While Dox-induced expression
of Smad7 could induce formation of AP-positive colonies and
enhanced expression of pluripotency markers, knockdown of
STAT3 markedly attenuated the effect of Smad7 (Fig. S6 A and
B). Conversely, whereas Smad7 depletion reduced the mRNA
levels of pluripotency markers and abolished production of
LIF-induced AP-positive colonies, overexpression of STAT3C
(a constitutively active mutant of STAT3) completely rescued
pluripotency in Smad7-depleted cells (Fig. S6 C and D).
Moreover, JAK inhibitor Filgotinib also strongly attenuated
the effect of Smad7 in ESC pluripotency (Fig. S6E). These
results suggest that Smad7 stimulates stemness through JAK-
dependent STAT3 activation.
Although overexpression of SHP2 or SOCS3 reduced ESC colony
formation, ectopic expression of Smad7 could reverse the action of
SOCS3 or SHP2 to rescue ESC colony formation (Fig. 5E and Fig.
S6F), STAT3 activation, and expression of Oct4, Sox2, and Nanog
(Fig. S6G). Conversely, knockdown of Smad7 alone attenuated
STAT3 activation and ESC pluripotency (Figs. 4D and 5F and Fig.
S6 C andH). Notably, simultaneous double knockdown of SHP2 and
SOCS3 in Smad7-depleted ESCs could restore AP-positive colony
formation (Fig. 5F and Fig. S6H) and expression of pluripotency
markers (Fig. S6I). Collectively, our findings illustrate that Smad7
antagonizes the negative role of SHP2 and SOCS3 in LIF/STAT3
signaling in pluripotency maintenance (Fig. 5G).
Discussion
Numerous investigations have elucidated the function of Smad7
in differentiated cells and adult stem cells. It is generally thought
that the primary function of Smad7 is to negatively impact
TGF-β/BMP signaling. However, Smad7 actions outside of the
TGF-β/BMP signaling have rarely been explored. A previous
study reported that Smad7 is highly expressed in undifferenti-
ated ESCs (41). Consistently, we found that expression of
Smad7 decreases during ESC differentiation (Fig. 1A and Fig.
S1A), implying a possible function of Smad7 in maintaining
ESC pluripotency. Here we report that Smad7 promotes ESC
self-renewal and attenuates ESC differentiation and identify
the direct role of Smad7 in maintaining pluripotency through a
gp130–STAT3-dependent yet TGF-β/BMP-independent sig-
naling pathway. In the current study, we not only reveal a
function of Smad7 in controlling pluripotency, but also offer
an underlying mechanism for previously unexplained signaling
interplays.
A few lines of experimental evidence convincingly demon-
strate the role of Smad7 in controlling pluripotency. First, in-
duced expression of Smad7 up-regulates expression of the core
pluripotency markers, whereas it down-regulates expression of
differentiation makers of all three germ-layer lineages (Fig. 1).
As a result, Smad7 promotes ESC colony formation. Second,
depletion of Smad7 severely attenuates expression of the core
pluripotency markers and colony formation and markedly en-
hances expression of differentiation makers in the ectoderm and
mesoderm lineages (Fig. 2 A–D and Fig. S2 B, E, and F). In
addition, we failed to generate complete knockout of the
Smad7 gene in mouse ESCs using the CRISPR/Cas9 technology,
implying the critical function of Smad7 in maintaining pluri-
potency. Third, depletion of Smad7 in MEFs drastically reduces
the reprogramming efficiency (Fig. 2 E and F). Together with the
molecular actions and interactions of Smad7 with the gp130–
STAT3 pathway, these findings support the important function
of Smad7 in maintaining pluripotency.
Although Smad7 is a well-established negative regulator in
TGF-β/BMP signaling, our study has clearly revealed that
Smad7 does not require TGF-β/BMP signaling to enable
STAT3 activation and maintenance of pluripotency (Fig. 3 and
Fig. S3). Small molecule inhibitors against TβRI or BMPRI fail
to reverse the effect of Smad7 depletion on attenuating STAT3
Fig. 4. Smad7 potently activates gp130-mediated STAT3 signaling. (A)
Smad7 stimulates LIF-induced STAT3 activation in ESCs. CGR8 control (Ctrl)
and SFB–Smad7–tet-on cells were cultured ± Dox (1 μg/mL, 72 h) and then
treated with LIF (0.1 ng/mL, 20 min). Cell lysates were subjected to Western
blot analysis. (B) Smad7 enhances SOCS3 expression in ESCs. SFB–Smad7–tet-
on or control cells were treated with or without 1 μg/mL Dox for 72 h. qRT-
PCR was used to examine the SOCS3 mRNA level. Data are shown as mean ±
SEM; n = 3. *P < 0.05. (C) Smad7 activates LIF-induced STAT3 signaling in-
dependent of TβRI or BMPRI in ESCs. WT and the K401E mutant of Smad7 are
indicated. CGR8 cell transfection, LIF treatment, and Western blot analysis
were done as described in Supporting Information. (D) Inhibition of TβRI/
BMPRI does not influence the effect of siSmad7 in LIF-induced STAT3 signaling in
ESCs. CGR8 cell transfection, LIF treatment, andWestern blot analysis were done
as described in Supporting Information.
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activation and pluripotency. Moreover, Smad7 mutants deficient
in binding to TβRI and BMPRI retain the ability to activate
STAT3 signaling and expression of pluripotency markers. These
results support the notion that Smad7 promotes STAT3 activation
independently of TGF-β/BMP signaling.
Instead, our work has revealed that Smad7 specifically pro-
motes pluripotency through the LIF–gp130–JAK–STAT3 pathway.
STAT3 depletion or JAK1 inhibitor blocks Smad7-mediated pro-
motion of ESC self-renewal. Moreover, constitutively activated
STAT3 completely reverses the effect of shSmad7 on ESC differ-
entiation. These results strongly suggest that Smad7 promotes LIF-
induced STAT3 activation to stimulate ESC pluripotency. Our
work has further revealed the molecular mechanism underlying
Smad7-induced STAT3 signaling in pluripotency. Smad7 directly
interacts with the cytoplasmic domain of gp130 (Fig. 5 A and B and
Fig. S5A) and blocks the binding of SHP2 or SOCS to gp130,
thereby ensuring the maintenance or amplification of STAT3 ac-
tivation (Fig. 5 C and D). Indeed, ectopic expression of Smad7 can
override the negative action of SOCS3 or SHP2 to rescue ESC
pluripotency (Fig. 5E and Fig. S6 F andG), whereas the destructive
effect of Smad7 depletion on STAT3 activation and ESC pluri-
potency can be counterbalanced by simultaneous knockdown of
SHP2 and SOCS3 (Fig. 5F and Fig. S6 H and I). Collectively, our
findings illustrate that Smad7-mediated disruption of the SHP2/
SOCS3-dependent negative impact in LIF/STAT3 signaling is an
essential regulatory means in pluripotency maintenance (Fig. 5G).
Our study also implicates that TGF-β/BMP signaling may regu-
late pluripotency through various mechanisms. Previous reports
mostly attribute the actions of TGF-β/BMP signaling in controlling
pluripotency to their direct role in regulating cell proliferation and
differentiation. For example, Activin/Nodal/TGF-β is indispensable
for ESC propagation (7), while BMP induces Id proteins to sup-
press differentiation and sustain ESC self-renewal (6). Providing the
fact that Smad7 is induced by TGF-β/BMP signaling, it is plausible
that Smad7 can act as an effector in mediating TGF-β/BMP sig-
naling likely in promoting STAT3 activation. In addition, the BMP–
Smad signaling and LIF–STAT3 pathways collaboratively control
the maintenance of mouse ESC self-renewal (5). Smad1/5/8 can
cooperate with the core pluripotency factors to maintain pluri-
potency (39). BMP increases LIF responsiveness in epiblast stem
cells through a p300-bridged complex between Smad1 and STAT3
(47). Our study adds another layer of signaling cross-talk that
BMP4-induced Smad7 may act to sensitize ESCs to respond to LIF
in activating STAT3. Thus, as a transcriptional product in response
to TGF-β/BMP ligands, Smad7 may positively effectuate certain
TGF-β/BMP-induced responses such as pluripotency control.
Therefore, in addition to its well-established role in blocking
canonical TGF-β–Smad signaling via binding to the TGF-β/BMP
type I receptor, Smad7 can exert its cellular function through
Fig. 5. Smad7 directly competes with SHP2/SOCS3 for gp130 binding and enables STAT3 signaling in maintaining pluripotency. (A) Smad7 interacts with
gp130 under physiological conditions. Immunoprecipitation and Western blot analysis were done as described in Supporting Information. (B) Smad7 directly
interacts with gp130. In vitro binding was carried out with purified His–gp130–ICD and in vitro translated Smad7. Experimental details are described in
Supporting Information. (C) Smad7 displaces SHP2 on gp130. Increasing concentrations of purified His–Smad7 proteins were added to the gp130Y759E–
SHP2 complex, and followed by Western blot analysis with indicated antibodies. (D) Smad7 competes with endogenous SHP2 and SOCS3 for gp130 binding in
CGR8 cells. Cell lysates were immunoprecipitated with anti-SOCS3 antibody or anti-SHP2 antibody. Cell culture, LIF treatment, immunoprecipitation, and
Western blot analysis were done as indicated and described in Supporting Information. (Left) SFB–Smad7–tet-on cells treated with or without Dox; (Right)
CGR8 cells with shCtrl and shSmad7. In the bottom blots, FLAG/Smad7 means the use of anti-FLAG in lanes 1–4 and anti-Smad7 in lanes 5–8. (E)
Smad7 overcomes SHP2- or SOCS3-mediated suppression of ESC colony formation. CGR8 cell transfection and AP staining were performed as described in
Supporting Information. The bar graph represents the fold change of numbers of uniform AP+ colonies in Fig. S6F. Data are shown as mean ± SEM; n = 3. *P <
0.05. (F) SiSmad7 inhibition of ESC self-renewal is reversed by simultaneous knockdown of SHP2 and SOCS3. Experiments and data analysis were done as
described in Fig. 5E and Supporting Information. The bar graph represents the fold change of numbers of uniform AP+ colonies in Fig. S6H. Data are shown as
mean ± SEM; n = 3. *P < 0.05. (G) A working model for Smad7 potentiating STAT3 activation. (Left) LIF and related cytokines (C) bind to the gp130 receptor
complex. Receptor-associated JAK kinases phosphorylate STAT3 leading to STAT3 accumulation in the nucleus, where STAT3 controls expression of target
genes, including Smad7 and SOCS3. SOCS3 and SHP2 bind to gp130 to inhibit STAT3 activation. Smad7 can compete for the gp130 binding, maintaining
STAT3 activation. (Right) Active and inactive forms of the cytokine-receptor–gp130 complex are shown.








direct binding to a cytokine receptor and enhancement of
downstream STAT3 signaling. Because the interplay between
TGF-β and gp130–STAT3 signaling exists in various physiolog-
ical contexts, it is conceivable that through its interaction with
the gp130–STAT3 axis, Smad7 may have a broader role in
bridging the collaborative functions of the TGF-β–Smad and
gp130–STAT3 signaling pathways in other pathophysiological
processes such as inflammation and tumorigenesis.
Materials and Methods
Cell Culture, Transfection, Immunoprecipitation, Immunofluorescence, qRT-PCR,
and Western Blotting. Culture and transfection of CGR8, HEK293T, C2C12, and
HaCaT cell lines, and subsequentmolecular analysis were done as described in
Supporting Information.
Secondary Colony Formation Assay and Alkaline Phosphatase Staining. Es-
tablishment of CGR8 and its stable lines with Dox-induced expression or
knockdown of Smad7, cell transfection, LIF treatment, colony formation,
and alkaline phosphatase staining were carried out as described in
Supporting Information.
Full materials and methods are outlined in Supporting Information.
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